Business Wire

Forescout Addresses Modern SecOps Challenges with Launch of Forescout XDR

1.3.2023 18:00:00 EET | Business Wire | Press release

Share

Forescout Technologies Inc., the global leader in automated cybersecurity, today unveiled Forescout XDR, to help enterprises better detect, investigate, and respond to the broadest range of advanced threats, across the extended enterprise.

A typical SOC is flooded with 450 alerts per hour1, and analysts waste precious time trying to correlate low fidelity alerts and chasing false positives, often at the expense of focusing on legitimate attacks. Until now, a security operations center’s (SOC) field of view for threat detection and response has excluded critical devices that are increasingly common points of attack, including operational technology (OT), industrial control systems (ICS), building management systems (BMS), and medical and IoT devices. In addition, the technology stack that SecOps teams have had to rely on has made it difficult to respond to these threats in a rapid and comprehensive manner.

“The true value of an XDR solution lies in its ability to ingest telemetry and data from across the entire enterprise: cloud, campus, remote and datacenter environments, and every managed and unmanaged connected device. This is what the X in XDR is all about, after all,” said Justin Foster, CTO, Forescout. “Traditional XDR products lack this capability, or they only leverage data from the vendor’s own EDR or a few other security tools. This significantly limits the flexibility, scalability and effectiveness that an XDR solution must provide.”

Through the advanced application of data science and automation, Forescout XDR generates one high-fidelity alert that truly warrants analyst investigation, from every 50 million logs ingested, per hour2. Because Forescout XDR is vendor- and EDR-agnostic, this ingestion includes data from over 170 security, infrastructure, application, cloud/SaaS and enrichment sources, and dozens of leading vendors. And with over 70 sources of threat intelligence and 1500 verified detection rules and models, and data onboarding included, Forescout XDR customers can be operational within hours, actively detecting, investigating, and responding to threats.

“Forescout XDR, with the breadth and richness of its capabilities, particularly its dashboards and reporting, provides an out-of-the-box solution to SOC challenges that we spent 18-24 months trying to address,” said Samer Mansour, CISO, Panasonic Corporation of North America. “It was easy to deploy, and fully operational in a matter of weeks. And with its tight integration to Forescout’s network security and visibility solutions, and our broader security tech stack, it gives us the ability to exert a lot more control across our IT and OT environments, and further elevate our overall security.”

Seamless integration with Forescout’s industry-leading network access control solution helps ensure that customers can:

  1. Reduce the attack surface, and the risk of an attack in the first place, by preventing compromised or non-compliant devices from connecting to their networks. This proactive approach to XDR further elevates the effectiveness and performance of a modern SOC.
  2. Automate response workflows that can immediately touch every managed and unmanaged connected device, across the enterprise. This reduces an attack's blast radius in real-time, allowing proper mitigation or remediation measures to be completed.

Because Forescout XDR has a multi-tenant architecture and supports local data storage while also being able to provide an aggregated global view of threats and SOC performance, it is ideally suited to large enterprises, multi-nationals, organizations with regional SOCs and managed security service providers (MSSPs).

Pricing
SaaS licensing is based on the total number of endpoints in the enterprise. As such, customers have the flexibility to leverage the data sources needed to fully support the use cases important to them, and help ensure better detection, without concern for escalating or fluctuating costs associated with cloud log storage.

About Forescout
Forescout Technologies, Inc. delivers automated cybersecurity across the digital terrain, maintaining continuous alignment of customers’ security frameworks with their digital realities, including all asset types- IT, IoT, OT, IoMT, and cloud environments. The Forescout Platform provides complete asset visibility, continuous compliance, network segmentation and a strong foundation for Zero Trust. For more than 20 years, Fortune 100 organizations and government agencies have trusted Forescout to provide automated cybersecurity at scale. Forescout arms customers with data-powered intelligence to accurately detect risks and quickly remediate cyberthreats without disruption of critical business assets. www.forescout.com

Managing cyber risk, together.

1

“The 2020 State of Security Operations,” Forrester Consulting

2

Based on aggregate Forescout data from a 1-year period (Dec 2021-2022), across 30 enterprise customers, representing a range of company sizes and industries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contact:
Emily Alfano
Manager of PR
Emily.alfano@forescout.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye